These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35793453)

  • 1. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.
    Ha SYY; Anami Y; Yamazaki CM; Xiong W; Haase CM; Olson SD; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Mol Cancer Ther; 2022 Sep; 21(9):1449-1461. PubMed ID: 35793453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Zanotto I; Cannella L; Gabbia D; Matsuno Y; Suzuki A; Yoshioka H; Armirotti A; De Martin S; Pasut G
    J Control Release; 2024 Nov; 375():74-89. PubMed ID: 39216599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.
    Anami Y; Yamazaki CM; Xiong W; Gui X; Zhang N; An Z; Tsuchikama K
    Nat Commun; 2018 Jun; 9(1):2512. PubMed ID: 29955061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
    Amin TU; Emara R; Pal A; Aldawod H; Jiang G; Liang D; Haque Tuhin MT; Balgoname A; Patel AD; Alhamadsheh MM
    J Med Chem; 2022 Nov; 65(22):15473-15486. PubMed ID: 36327103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and Characterization of Iduronidase-Cleavable ADCs.
    Jäger S; Könning D; Rasche N; Hart F; Sensbach J; Krug C; Raab-Westphal S; Richter K; Unverzagt C; Hecht S; Anderl J; Schröter C
    Bioconjug Chem; 2023 Dec; 34(12):2221-2233. PubMed ID: 38054705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise.
    Zhao H; Gulesserian S; Malinao MC; Ganesan SK; Song J; Chang MS; Williams MM; Zeng Z; Mattie M; Mendelsohn BA; Stover DR; Doñate F
    Mol Cancer Ther; 2017 Sep; 16(9):1866-1876. PubMed ID: 28522588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity.
    Rady T; Turelli L; Nothisen M; Tobaldi E; Erb S; Thoreau F; Hernandez-Alba O; Cianferani S; Daubeuf F; Wagner A; Chaubet G
    Bioconjug Chem; 2022 Oct; 33(10):1860-1866. PubMed ID: 36106863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
    Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
    AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
    Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
    Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.